Day One Biopharmaceuticals (NASDAQ:DAWN) Stock Rating Reaffirmed by Wedbush

Wedbush reaffirmed their outperform rating on shares of Day One Biopharmaceuticals (NASDAQ:DAWN) in a report published on Thursday morning, RTT News reports. They currently have a $33.00 price target on the stock.

DAWN has been the topic of a number of other reports. Needham & Company LLC restated a buy rating and set a $33.00 price objective on shares of Day One Biopharmaceuticals in a research report on Wednesday, June 19th. HC Wainwright restated a buy rating and set a $40.00 price objective on shares of Day One Biopharmaceuticals in a research report on Thursday, June 20th. Piper Sandler restated an overweight rating and set a $40.00 price objective on shares of Day One Biopharmaceuticals in a research report on Monday, July 8th. Finally, JPMorgan Chase & Co. boosted their price target on Day One Biopharmaceuticals from $32.00 to $36.00 and gave the company an overweight rating in a research note on Monday, April 22nd. One equities research analyst has rated the stock with a hold rating and six have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of Moderate Buy and an average target price of $37.67.

Day One Biopharmaceuticals Stock Up 0.9 %

Shares of NASDAQ DAWN opened at $16.03 on Thursday. The business’s 50 day moving average is $14.01 and its two-hundred day moving average is $14.82. The company has a market cap of $1.40 billion, a P/E ratio of -6.39 and a beta of -1.51. Day One Biopharmaceuticals has a 12 month low of $9.67 and a 12 month high of $18.07.

Day One Biopharmaceuticals (NASDAQ:DAWN) last released its quarterly earnings data on Monday, May 6th. The company reported ($0.72) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.67) by ($0.05). Sell-side analysts expect that Day One Biopharmaceuticals will post -2.69 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Day One Biopharmaceuticals news, insider Samuel C. Blackman sold 10,000 shares of the business’s stock in a transaction on Friday, May 10th. The stock was sold at an average price of $16.37, for a total value of $163,700.00. Following the transaction, the insider now owns 1,164,662 shares of the company’s stock, valued at $19,065,516.94. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. In other Day One Biopharmaceuticals news, CFO Charles N. York II sold 52,183 shares of the business’s stock in a transaction on Wednesday, May 1st. The stock was sold at an average price of $17.89, for a total value of $933,553.87. Following the transaction, the chief financial officer now owns 225,571 shares of the company’s stock, valued at $4,035,465.19. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, insider Samuel C. Blackman sold 10,000 shares of the business’s stock in a transaction on Friday, May 10th. The stock was sold at an average price of $16.37, for a total value of $163,700.00. Following the completion of the transaction, the insider now directly owns 1,164,662 shares in the company, valued at approximately $19,065,516.94. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 195,534 shares of company stock valued at $3,367,830. 8.40% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Day One Biopharmaceuticals

Several large investors have recently made changes to their positions in DAWN. Wellington Management Group LLP lifted its stake in shares of Day One Biopharmaceuticals by 5.0% during the third quarter. Wellington Management Group LLP now owns 117,576 shares of the company’s stock valued at $1,443,000 after acquiring an additional 5,566 shares during the period. Vanguard Group Inc. lifted its stake in shares of Day One Biopharmaceuticals by 8.1% during the third quarter. Vanguard Group Inc. now owns 4,629,754 shares of the company’s stock valued at $56,807,000 after acquiring an additional 346,090 shares during the period. SG Americas Securities LLC lifted its stake in shares of Day One Biopharmaceuticals by 74.9% during the fourth quarter. SG Americas Securities LLC now owns 64,692 shares of the company’s stock valued at $945,000 after acquiring an additional 27,712 shares during the period. China Universal Asset Management Co. Ltd. lifted its stake in shares of Day One Biopharmaceuticals by 352.2% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 10,067 shares of the company’s stock valued at $147,000 after acquiring an additional 7,841 shares during the period. Finally, Arizona State Retirement System lifted its stake in shares of Day One Biopharmaceuticals by 8.2% during the fourth quarter. Arizona State Retirement System now owns 13,373 shares of the company’s stock valued at $195,000 after acquiring an additional 1,010 shares during the period. Institutional investors and hedge funds own 87.95% of the company’s stock.

Day One Biopharmaceuticals Company Profile

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.